Grant of Interim Extension of the Term of U.S. Patent No. 7,534,790; Vernakalant Hydrochloride, 19459 [2020-07190]

Download as PDF Federal Register / Vol. 85, No. 67 / Tuesday, April 7, 2020 / Notices All catch would be attributed to the appropriate commercial fishing quota. For a vessel fishing on a groundfish sector trip, all catch of groundfish stocks allocated to sectors would be deducted from the vessel’s sector’s annual catch entitlement (ACE). Once the ACE for a stock has been reached in a sector, vessels would no longer be allowed to fish in that stock area unless the sector acquired additional ACE for the stock in question. For common pool vessels, all groundfish catch would be counted toward the appropriate trimester total allowable catch (TAC). Common pool vessels would be exempt from possession and trip limits on EFP trips when directed for sampling by the Center, but would still be subject to trimester TAC closures. If approved, the Center may request minor modifications and extensions to the EFP throughout the year. EFP modifications and extensions may be granted without further notice if they are deemed essential to facilitate completion of the proposed research and have minimal impact that does not change the scope of the initially approved EFP request. Any fishing activity conducted outside the scope of the exempted fishing activity would be prohibited. Authority: 16 U.S.C. 1801 et seq. Dated: April 1, 2020. He´le`ne M.N. Scalliet, Acting Director, Office of Sustainable Fisheries,National Marine Fisheries Service. [FR Doc. 2020–07218 Filed 4–6–20; 8:45 am] BILLING CODE 3510–22–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No.: PTO–P–2020–0021] Grant of Interim Extension of the Term of U.S. Patent No. 7,534,790; Vernakalant Hydrochloride United States Patent and Trademark Office, Commerce. ACTION: Notice of interim patent term extension. AGENCY: khammond on DSKJM1Z7X2PROD with NOTICES VerDate Sep<11>2014 18:22 Apr 06, 2020 Jkt 250001 Robert Bahr, Deputy Commissioner for Patent Examination Policy,United States Patent and Trademark Office. [FR Doc. 2020–07190 Filed 4–6–20; 8:45 am] BILLING CODE 3510–16–P The United States Patent and Trademark Office has issued an order granting interim extension for a oneyear interim extension of the term of U.S. Patent No. 7,534,790. FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272–0909; by mail marked to his attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to his attention at SUMMARY: (571) 273–0909; or by email to ali.salimi@uspto.gov. SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On February 5, 2020, Correvio International Sa`rl, the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a second interim extension of the term of U.S. Patent No. 7,534,790. The patent claims the human drug product, vernakalant hydrochloride. The application for patent term extension indicates that New Drug Application (NDA) 22–034 was submitted to the Food and Drug Administration (FDA) on December 19, 2006. Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the once-extended expiration date of the patent, March 31, 2020, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,534,790 is granted for a period of one year from the extended expiration date of the patent. COMMODITY FUTURES TRADING COMMISSION Sunshine Act Meetings 1:30 p.m. EDT, Tuesday, April 14, 2020. PLACE: This meeting will be convened on a telephone conference call. STATUS: Closed. MATTERS TO BE CONSIDERED: Enforcement matters. In the event that TIME AND DATE: PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 19459 the time, date, or location of this meeting changes, an announcement of the change, along with the new time, date, and/or place of the meeting will be posted on the Commission’s website at https://www.cftc.gov/. CONTACT PERSON FOR MORE INFORMATION: Christopher Kirkpatrick, 202–418–5964. Authority: 5 U.S.C. 552b. Dated: April 3, 2020. Christopher Kirkpatrick, Secretary of the Commission. [FR Doc. 2020–07422 Filed 4–3–20; 4:15 pm] BILLING CODE 6351–01–P CORPORATION FOR NATIONAL AND COMMUNITY SERVICE Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Application Instructions for AmeriCorps State and National Competitive New and Continuation Corporation for National and Community Service (CNCS). ACTION: Notice of information collection; request for comment. AGENCY: In accordance with the Paperwork Reduction Act of 1995, CNCS is proposing to renew an information collection. DATES: Written comments must be submitted to the individual and office listed in the ADDRESSES section by June 8, 2020. ADDRESSES: You may submit comments, identified by the title of the information collection activity, by any of the following methods: (1) By mail sent to: Corporation for National and Community Service, Attention Arminda Pappas, 250 E Street SW, Washington, DC 20525. (2) By hand delivery or by courier to the CNCS mailroom at the mail address given in paragraph (1) above, between 9:00 a.m. and 4:00 p.m. Eastern Time, Monday through Friday, except federal holidays. (3) Electronically through www.regulations.gov. Comments submitted in response to this notice may be made available to the public through regulations.gov. For this reason, please do not include in your comments information of a confidential nature, such as sensitive personal information or proprietary information. If you send an email comment, your email address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the SUMMARY: E:\FR\FM\07APN1.SGM 07APN1

Agencies

[Federal Register Volume 85, Number 67 (Tuesday, April 7, 2020)]
[Notices]
[Page 19459]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07190]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2020-0021]


Grant of Interim Extension of the Term of U.S. Patent No. 
7,534,790; Vernakalant Hydrochloride

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting interim extension for a one-year interim extension of 
the term of U.S. Patent No. 7,534,790.

FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272-
0909; by mail marked to his attention and addressed to the Commissioner 
for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 
22313-1450; by fax marked to his attention at (571) 273-0909; or by 
email to [email protected].

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On February 5, 2020, Correvio International S[agrave]rl, the patent 
owner of record, timely filed an application under 35 U.S.C. 156(d)(5) 
for a second interim extension of the term of U.S. Patent No. 
7,534,790. The patent claims the human drug product, vernakalant 
hydrochloride. The application for patent term extension indicates that 
New Drug Application (NDA) 22-034 was submitted to the Food and Drug 
Administration (FDA) on December 19, 2006.
    Review of the patent term extension application indicates that, 
except for permission to market or use the product commercially, the 
subject patent would be eligible for an extension of the patent term 
under 35 U.S.C. 156, and that the patent should be extended for one 
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory 
review period will continue beyond the once-extended expiration date of 
the patent, March 31, 2020, interim extension of the patent term under 
35 U.S.C. 156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 7,534,790 is granted for a period of one year from the 
extended expiration date of the patent.

Robert Bahr,
Deputy Commissioner for Patent Examination Policy,United States Patent 
and Trademark Office.
[FR Doc. 2020-07190 Filed 4-6-20; 8:45 am]
BILLING CODE 3510-16-P